UroGen Pharma Ltd.
URGN
Positions held
Your positionsURGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- UroGen Pharma Ltd. operates in the biotechnology sector, which is experiencing rapid growth due to increasing demand for innovative therapies and advancements in drug development.
- Revenue increased by 42% compared to the prior quarter, reaching $72 million.
- Gross margin remains strong at 90.9%, demonstrating the company's ability to maintain profitability despite challenges.
- The company has a negative profit margin of -51.73%, indicating ongoing financial struggles.
- Net income for the most recent quarter was -$14.351 million, reflecting continued losses.
- Operating margin has been volatile, with a recent expansion to only 0.2%, highlighting operational inefficiencies.
Fundamentals
| Market cap | $1.81B | Enterprise value | $1.90B | Trailing P/E | — | Forward P/E | 13.23 |
| PEG | — | Price / book | -13.65 | Beta | 1.58 | Dividend yield | 0.00% |
| Revenue growth | 2.0% | Earnings growth | — | Gross margin | 90.8% | Operating margin | 0.2% |
| Profit margin | -51.7% | ROE | — | ROA | -18.1% | Debt / equity | — |
| Current ratio | 3.80 | Free cash flow | -$106.98M | Analyst recommendation | strong_buy | Mean target | $60.00 |
| 52w high | $50.81 | 52w low | $15.86 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $72.5M | $51.0M | $37.8M | $27.5M | $24.2M | — |
| Op margin | 0.2% | -39.8% | -50.5% | -99.7% | -171.2% | — |
| Net income | -$14.4M | -$23.6M | -$26.4M | -$33.3M | -$49.9M | — |
| Gross margin | 90.9% | 91.9% | 91.3% | 88.1% | 85.3% | — |
| Gross profit | $65.9M | $46.8M | $34.5M | $24.2M | $20.7M | — |
| Operating income | $0.1M | -$20.3M | -$19.1M | -$27.4M | -$41.4M | — |
- Revenue +42% vs prior quarter ($72M vs $51M).
- Gross margin 90.9% (was 91.9% prior quarter).
- Operating margin expanded to 0.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $110M | $90.4M | $82.7M | $64.4M | — |
| Op margin | -113.7% | -107.1% | -79.2% | -122.8% | — |
| Net income | -$153M | -$127M | -$102M | -$110M | — |
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | — |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | — |
| Operating income | -$125M | -$96.8M | -$65.5M | -$79.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Here's Why You Should Add URGN Stock to Your Portfolio Now
2026-09-25 · UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base
2026-09-23 · Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?
2026-09-23 · Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?
2026-09-09 · Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
2026-09-04 · UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · UroGen Pharma to Present at Upcoming Investor Conferences
2026-08-24 · Urogen Pharma Insider Sold Shares Worth $2,854,853, According to a Recent SEC Filing
2026-08-21 · Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
2026-08-20 · UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform
Price (daily)
Full chart · RSI · MACD · patterns